Disability from long-term rheumatoid arthritis reduced with biologic treatmentJune 13, 2007New data demonstrating the safety and efficacy of Enbrel® (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term. Biologics, such as etanercept, work by blocking the action of a naturally occurring protein in the body called 'tumor necrosis factor' that is involved in causing inflammation (2). When combined with methotrexate, etanercept, also known as an anti-TNF therapy, has been shown to halt radiographic damage in patients with moderate RA activity over multiple years - which means the disease is halted at that stage (3). Professor Lars Klareskog of Karolinska Institute Karolinska University Sweden, said, "These strong data should give doctors the confidence to consider a biologic earlier in patients with aggressive and progressive rheumatoid arthritis, and patients should now have the prospect of less disability with a treatment which has also proven to have a good long-term safety". The analysis includes over nine thousand patient years of data from a total of 2,054 patients who were monitored for serious adverse events (SAEs), serious and opportunistic infections, sepsis, malignancies and lymphomas. Overall rates of SAE's were similar to control groups (0.11 pt-yr and 0.17 pt/yr vs 0.11-0.20/pt yr), as were serious infections, and reports of opportunistic infection were rare (1). Professor Emilio Martin Mola of the Rheumatology Unit at Hospital Universitario La Paz, Spain added: "With both earlier and continuous use of Enbrel we can prevent the debilitating affects of RA taking hold and maintain this response for many years. It's critical that appropriate funding for biologics is sourced to continue the fight against serious inflammatory diseases, such as RA." The economic burden created by RA in Europe is significant due to costs from work disability and 20-30% of patients become permanently disabled during the first two or three years of the disease (4). This latest study adds to the clinical evidence highlighting the role of prevention of disease progression through earlier anti-TNF treatment. Given the significant social and economical burden of this disease this makes good sense for patients and healthcare systems alike. Enbrel has a well characterized safety profile and is well tolerated. Although a rare event, a higher than expected rate of lymphoma was observed in the analysis. However, further study is required to establish whether this is related to TNF antagonist exposure or reflects the elevated risk of lymphoma in patients with RA. About Rheumatoid Arthritis (RA) Rheumatoid arthritis (RA) is a chronic inflammatory disease that typically affects the hands and feet although any joint lining may be affected (5). If the condition persists over time, it can cause permanent damage to tendons, ligaments, cartilage and bone, resulting in potential destruction and deformity (5). Potential irreversible joint damage may lead to loss of function and premature death (6). RA is also associated with serious morbidities including coronary artery disease infection and lymphoma (7). 1) Klareskog L. Safety and Efficacy of Over 9 Years of Continuous Etanercept Therapy in Patients with Rheumatoid Arthritis in North America and Europe, EULAR Congress 2007, Poster No. THU0170 2) Weaver, A L, the Impact of new biologicals in the treatment of Rheumatoid Arthritis Rheumatology 2004;43 (Suppl.3):iii17-iii23 3) van der Heijde, D. et al. Combination etanercept and methotrexate halts radiographic damage in patients with moderate RA activity on methotrexate, EULAR Congress 2007, Poster No. THU0213 4) Sokka T. Work disability in early rheumatoid arthritis. Clinical and Experimental Rheumatology 2003;21 (Suppl.31) S71-S74 5) Lee DM, Weinblatt ME. Rheumatoid arthritis Lancet 2001; 358: 903-911 6) Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995;8:229-41 7) Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 2001;27:269-281 Ketchum |
|||||||||||||||||||||
| Related Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Pain thresholds linked to inflammation and sleep problems in arthritis patients Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute. Grains and lamb offer new sources of omega-3 CSIRO research on grains and lamb aimed at developing new dietary sources of long-chain omega-3 oils will be presented at the World Congress on Oils and Fats in Sydney this week. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. Experimental approach may reverse rheumatoid arthritis and osteoporosis Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation. Promising new target emerges for autoimmune diseases University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. New 'biofactories' produce rare healing substances in the endangered Devil's claw plant Deep in Africa's Kalahari Desert lies the "Devil's claw," a plant that may hold the key to effective treatments for arthritis, tendonitis and other illnesses that affect millions each year. More Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||